Regeneron and Sanofi’s Dupixent FDA-approved for eosinophilic esophagitis
The approval is the first that the Food and Drug Administration has granted for a drug intended to treat eosinophilic esophagitis, a chronic immune disorder.
Archives for May 23, 2022
Dermatology drug developer taps into Veeva engagement tool
With Veeva Link for Key People, LEO Pharma is looking to deepen its efforts to engage with knowledgeable medical professionals in the dermatology community.